AbbVie is a research-based biopharmaceutical company focused on developing and marketing innovative therapies in several key therapeutic areas including immunology, oncology, neuroscience, and ophthalmology.
An examination of a recently matured debt instrument reveals comprehensive details regarding a bond issued by AbbVie, a globally recognized biopharmaceutical company. AbbVie Inc., headquartered in North Chicago, Illinois, stands as a prominent player in the pharmaceutical industry, having been spun off from Abbott Laboratories in 2013. The company is intensely focused on discovering, developing, manufacturing, and selling advanced therapies across several critical therapeutic areas, including immunology, oncology, neuroscience, and virology, establishing a strong market presence through its innovative pipeline and diverse product portfolio that underpins its financial strength. The specific obligation, bearing the ISIN code USU0029QAZ91 and CUSIP U0029QAZ9, was issued from the United States with a total original issue size of USD 2,627,036,000, and a minimum purchase lot of USD 2,000. This bond offered a fixed annual interest rate of 3.45%, with payments distributed semi-annually in USD. Critically, the instrument matured on March 15, 2022, and at that point, its market price stood at 100% of par, confirming that it was fully redeemed and principal was repaid to investors as scheduled. Prior to its maturity, the bond carried a credit rating of 'BBB+' from Standard & Poor's (S&P), categorizing it as an upper-medium investment-grade bond, indicative of AbbVie's sound financial health and ability to meet its debt obligations. This particular AbbVie bond has therefore successfully completed its lifecycle, having been fully repaid and retired from the market.
|
Français
Italiano
United States
USU0029QAZ91 ( in USD )
